Cargando…
Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
SIMPLE SUMMARY: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, mostly driven by activating mutations in KIT or PDGFRα oncogenes. The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of GIST resulting in...
Autores principales: | van de Wal, Deborah, Elie, Mai, Le Cesne, Axel, Fumagalli, Elena, den Hollander, Dide, Jones, Robin L., Marquina, Gloria, Steeghs, Neeltje, van der Graaf, Winette T. A., Husson, Olga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997462/ https://www.ncbi.nlm.nih.gov/pubmed/35406604 http://dx.doi.org/10.3390/cancers14071832 |
Ejemplares similares
-
Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022) -
Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry
por: IJzerman, Nikki S., et al.
Publicado: (2020) -
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023) -
Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
por: van de Wal, Deborah, et al.
Publicado: (2023) -
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)